Antibody Drug Conjugates (ADCs) are targeted cancer therapies designed to deliver chemotherapy agents directly to cancer cells through a monoclonal antibody connected by a chemical linker. This targeted mechanism helps improve treatment effectiveness while minimizing damage to healthy cells and reducing chemotherapy-related side effects.

ADCs are transforming precision oncology by combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. Advancements in linker technologies and payload engineering are accelerating the development of next-generation ADC therapies across multiple cancer indications.

Market Size and Growth

The global ADC market demonstrated strong growth in 2023, reaching a valuation of approximately USD 5.48 billion. Supported by expanding clinical pipelines, increasing regulatory approvals, and rising investments in oncology therapeutics, the market is projected to reach approximately USD 8.42 billion by 2025.

The market is expected to grow at a CAGR of 22.0% during the forecast period from 2026 to 2035.

Major Companies in the ADC Market

AstraZeneca

AstraZeneca is among the leading players in the ADC market, particularly through its strategic collaboration with Daiichi Sankyo. The company considers ADCs a core component of its precision oncology strategy, focusing on breast cancer, lung cancer, gastric cancer, and gynecologic cancers.

Company Overview

• Founded: 1999
• Headquarters: Cambridge, United Kingdom
• Employees: Approximately 96,100
• Revenue: USD 58.7 billion

Regional Presence

AstraZeneca operates across major regions including:

• United States
• Europe
• Emerging Markets
• India
• China
• Japan
• Canada

Major ADC Products and Pipeline

Pfizer

Pfizer significantly expanded its ADC business after acquiring Seagen in 2023 for approximately USD 43 billion.

Focus Areas

• Oncology therapeutics
• Targeted drug delivery
• Next-generation ADC platforms
• Combination immunotherapy and ADC treatments

Company Overview

• Founded: 1849
• Employees: Approximately 75,000
• Revenue: Approximately USD 62.6 billion

Gilead Sciences

Gilead became a major ADC participant following its acquisition of Immunomedics in 2020.

Strategic Strengths

• Trodelvy ADC platform
• TROP-2 targeting expertise
• Strong breast cancer portfolio
• Expansion into next-generation ADC technologies

Company Overview

• Founded: 1987
• Headquarters: Foster City, California, USA
• Employees: Approximately 17,000
• Revenue: Approximately USD 29.4 billion

Major ADC Products

ADC Therapeutics

ADC Therapeutics is a specialized biotechnology company focused exclusively on ADC development, particularly for hematologic malignancies.

Company Overview

• Founded: 2011
• Headquarters: Lausanne, Switzerland
• Employees: Approximately 265
• Revenue: Approximately USD 73–81 million

Major ADC Programs

AbbVie

AbbVie strengthened its ADC market position through the acquisition of ImmunoGen and continued development of oncology-focused ADC therapies.

Company Overview

• Founded: 2013
• Headquarters: North Chicago, Illinois, USA
• Employees: Approximately 57,000
• Revenue: Approximately USD 61.1 billion

Major ADC Products and Pipeline

GSK

GSK continues to strengthen its oncology portfolio through targeted cancer therapies, biologics innovation, and ADC collaborations.

Company Overview

• Founded: 2000
• Headquarters: London, United Kingdom
• Employees: Approximately 68,000
• Revenue: Approximately GBP 31–33 billion

Major ADC Programs

Kelun-Biotech

Kelun-Biotech has shown rapid growth through ADC commercialization and global licensing partnerships.

Company Overview

• Founded: 2016
• Headquarters: Chengdu, China
• Employees: Approximately 1,870–2,045
• Revenue: Approximately CNY 2.06 billion

Major ADC Pipeline

RemeGen

RemeGen has emerged as a strong ADC innovator with significant growth driven by Disitamab Vedotin commercialization and international partnerships.

Company Overview

• Founded: 2008
• Headquarters: Yantai, China
• Employees: Approximately 3,000+
• Revenue: Approximately CNY 3.25 billion

Major ADC Products and Pipeline

Key Developments

• Positive Phase 3 results for Disitamab Vedotin combined with toripalimab
• Strategic collaboration with Seagen for global development activities

Jiangsu Hengrui Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals is rapidly expanding its oncology-focused ADC pipeline through internal development and international licensing partnerships.

Company Overview

• Founded: 1970
• Headquarters: Lianyungang, China
• Employees: Approximately 20,600
• Revenue: Approximately USD 4.4 billion

Major ADC Pipeline

Rakuten Medical

Rakuten Medical is developing a specialized antibody conjugate therapy platform known as photoimmunotherapy (PIT).

Unlike traditional ADCs, the company uses antibody-dye conjugates activated by light to selectively destroy cancer cells.

Company Overview

• Founded: 2010
• Headquarters: San Diego, California, USA
• Employees: Approximately 300–500
• Lead Program: ASP-1929

ASP-1929 combines:

• Cetuximab (anti-EGFR antibody)
• IRDye®700DX light-activatable dye

Major Programs